Molecular Identification and Amphotericin B Susceptibility Testing of Clinical Isolates of Aspergillus From 11 Hospitals in Korea
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background: We investigated the species distribution and amphotericin B (AMB) susceptibility of Korean clinical Aspergillus isolates by using two Etests and the CLSI broth microdilution method. Methods: A total of 136 Aspergillus isolates obtained from 11 university hospitals were identified by sequencing the internal transcribed spacer (ITS) and β-tubulin genomic regions. Minimal inhibitory concentrations (MICs) of AMB were determined in Etests using Mueller-Hinton agar (Etest-MH) and RPMI agar (Etest-RPG), and categorical agreement with the CLSI method was assessed by using epidemiological cutoff values. Results: ITS sequencing identified the following six Aspergillus species complexes: Aspergillus fumigatus (42.6% of the isolates), A. niger (23.5%), A. flavus (17.6%), A. terreus (11.0%), A. versicolor (4.4%), and A. ustus (0.7%). Cryptic species identifiable by β-tubulin sequencing accounted for 25.7% (35/136) of the isolates. Of all 136 isolates, 36 (26.5%) had AMB MICs of ≥2 μg/mL by the CLSI method. The categorical agreement of Etest-RPG with the CLSI method was 98% for the A. fumigatus, A. niger, and A. versicolor complexes, 87% for the A. terreus complex, and 37.5% for the A. flavus complex. That of Etest-MH was ≤75% for the A. niger, A. flavus, A. terreus, and A. versicolor complexes but was higher for the A. fumigatus complex (98.3%). Conclusions: Aspergillus species other than A. fumigatus constitute about 60% of clinical Aspergillus isolates, and reduced AMB susceptibility is common among clinical isolates of Aspergillus in Korea. Molecular identification and AMB susceptibility testing by Etest-RPG may be useful for characterizing Aspergillus isolates of clinical relevance.
Abstract
Background: We investigated the species distribution and amphotericin B (AMB) susceptibility of Korean clinical Aspergillus isolates by using two Etests and the CLSI broth microdilution method. Methods: A total of 136 Aspergillus isolates obtained from 11 university hospitals were identified by sequencing the internal transcribed spacer (ITS) and β-tubulin genomic regions. Minimal inhibitory concentrations (MICs) of AMB were determined in Etests using Mueller-Hinton agar (Etest-MH) and RPMI agar (Etest-RPG), and categorical agreement with the CLSI method was assessed by using epidemiological cutoff values. Results: ITS sequencing identified the following six Aspergillus species complexes: Aspergillus fumigatus (42.6% of the isolates), A. niger (23.5%), A. flavus (17.6%), A. terreus (11.0%), A. versicolor (4.4%), and A. ustus (0.7%). Cryptic species identifiable by β-tubulin sequencing accounted for 25.7% (35/136) of the isolates. Of all 136 isolates, 36 (26.5%) had AMB MICs of ≥2 μg/mL by the CLSI method. The categorical agreement of Etest-RPG with the CLSI method was 98% for the A. fumigatus, A. niger, and A. versicolor complexes, 87% for the A. terreus complex, and 37.5% for the A. flavus complex. That of Etest-MH was ≤75% for the A. niger, A. flavus, A. terreus, and A. versicolor complexes but was higher for the A. fumigatus complex (98.3%). Conclusions: Aspergillus species other than A. fumigatus constitute about 60% of clinical Aspergillus isolates, and reduced AMB susceptibility is common among clinical isolates of Aspergillus in Korea. Molecular identification and AMB susceptibility testing by Etest-RPG may be useful for characterizing Aspergillus isolates of clinical relevance.
참고문헌 (25)
- Arendrup MC, "Update on antifungal resistance in Aspergillus and Candida", Clin Microbiol Infect, 20, pp.S42~48 (2014)
- Alastruey-Izquierdo A, "Current section and species complex concepts in Aspergillus: recommendations for routine daily practice", Ann N Y Acad Sci, 1273, pp.18~24 (2012)
- Balajee SA, "Molecular studies reveal frequent misidentification of Aspergillus fumigatus by morphotyping", Eukaryot Cell, 5, pp.1705~1712 (2006)
- Balajee SA, "Mistaken identity: Neosartorya pseudofischeri and its anamorph masquerading as Aspergillus fumigatus", J Clin Microbiol, 43, pp.5996~5999 (2005)
- Balajee SA, "Aspergillus species identification in the clinical setting", Stud Mycol, 59, pp.39~46 (2007)
- Lass-Flörl C, "In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis", J Antimicrob Chemother, 42, pp.497~502 (1998)
- Van Der Linden JW, "Aspergillus species intrinsically resistant to antifungal agents", Med Mycol, 49, pp.S82~89 (2011)
- Espinel-Ingroff A, "Wild-type MIC distributions and epidemiological cutoff values for amphotericin B and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document)", Antimicrob Agents Chemother, 55, pp.5150~5154 (2011)
- Kim MN, "Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features", Clin Infect Dis, 48, pp.e57~61 (2009)
- Al-Wathiqi F, "Molecular identification and antifungal susceptibility profile of Aspergillus flavus isolates recovered from clinical specimens in Kuwait", BMC Infect Dis, 13, pp.126~ (2013)
- Clinical and Laboratory Standards Institute, "Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard, 2nd ed. M38-A2", Clinical and Laboratory Standards Institute, ~ (2008)
- Shin JH, "Detection of amphotericin B resistance in Candida haemulonii and closely related species by use of the Etest, Vitek-2 yeast susceptibility system, and CLSI and EUCAST broth microdilution methods", J Clin Microbiol, 50, pp.1852~1855 (2012)
- Pfaller MA, "In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods", Antimicrob Agents Chemother, 57, pp.1065~1068 (2013)
- Perrone G, "Aspergillus niger contains the cryptic phylogenetic species A. awamori", Fungal Biol, 115, pp.1138~1150 (2011)
- Lass-Flörl C, "In vitro activities of various antifungal drugs against Aspergillus terreus: global assessment using the methodology of the European committee on antimicrobial susceptibility testing", Antimicrob Agents Chemother, 53, pp.794~795 (2009)
- Arendrup MC, "European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST). EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole", Clin Microbiol Infect, 18, pp.E248~250 (2012)
- Lass-Flörl C, "Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience", Br J Haematol, 131, pp.201~207 (2005)
- Balajee SA, "Molecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network", J Clin Microbiol, 47, pp.3138~3141 (2009)
- Steinbach WJ, "Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry", J Infect, 65, pp.453~464 (2012)
- Szekely A, "Comparison of E-test and broth microdilution methods for antifungal drug susceptibility testing of molds", J Clin Microbiol, 37, pp.1480~1483 (1999)
- Meletiadis J, "Comparison of the Etest and the sensititre colorimetric methods with the NCCLS proposed standard for antifungal susceptibility testing of Aspergillus species", J Clin Microbiol, 40, pp.2876~2885 (2002)
- Badiee P, "Antifungal susceptibility of the aspergillus species by Etest and CLSI reference methods", Arch Iran Med, 15, pp.429~432 (2012)
- Ozkutuk A, "Comparison of disk diffusion, E-test and broth microdilution test in determination of susceptibility of Aspergillus species to amphotericin B, itraconazole and voriconazole", J Chemother, 20, pp.87~92 (2008)
- Colozza C, "In vitro activities of amphotericin B and AmBisome against Aspergillus isolates recovered from Italian patients treated for haematological malignancies", Int J Antimicrob Agents, 39, pp.440~443 (2012)
- Barchiesi F, "Effects of amphotericin B on Aspergillus flavus clinical isolates with variable susceptibilities to the polyene in an experimental model of systemic aspergillosis", J Antimicrob Chemother, 68, pp.2587~2591 (2013)